炎症性肠病中的严重疲劳:莫达非尼多巴胺能治疗或硫胺素维生素治疗
本文是对Moulton等10例炎症性肠病合并慢性疲劳病例系列的评论。该系列中8例曾用多种精神药物,2例粪便钙卫蛋白升高提示活动性炎症性肠病;所有10例开放标签莫达非尼治疗后疲劳改善,基线平均疲劳评分16降至6个月后6.7。
要点
- 10例炎症性肠病合并慢性疲劳患者均对开放标签莫达非尼治疗有阳性反应。
- 基线自报平均疲劳评分16,治疗6个月后平均评分6.7(IBD-FAS量表)。
- 8例既往接受多种精神药物治疗,2例粪便钙卫蛋白升高提示活动性炎症性肠病。
核心结论
- 10例炎症性肠病合并慢性疲劳患者对开放标签莫达非尼治疗均呈阳性反应,疲劳症状显著改善。
研究设计与样本
- 本文为对Moulton等10例炎症性肠病合并慢性疲劳病例系列的评论。
主要发现
- 10例中8例既往接受多种精神药物治疗,2例粪便钙卫蛋白升高提示活动性炎症性肠病。
- 基线自报平均疲劳评分16(IBD-FAS量表上限20,高于11提示严重疲劳)。
- 开放标签莫达非尼治疗6个月后平均疲劳评分6.7。
关键数值与推荐
- IBD-FAS量表评分范围至20,高于11提示严重疲劳。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We found Moulton et al's1 illustrative case series of 10 patients with inflammatory bowel disease (IBD) and chronic fatigue, all presenting with depression, particularly interesting. 1 Among the patients, 8 previously had undergone treatment with multiple psychotropic medications, and 2 had active IBD as indicated by increased fecal calprotectin levels. Remarkably, all 10 patients responded positively to open-label treatment with modafinil, a central nervous system stimulant that blocks dopamine reuptake transport, which resulted in an impressive improvement in their fatigue symptoms. At baseline, the self-reported mean fatigue score was 16, measured on the IBD Fatigue Assessment Scale (IBD-FAS), which ranges up to 20, and with levels higher than 11 indicating severe fatigue. After 6 months of modafinil treatment, the mean fatigue score was 6.7.1.
引用
- Bager P, Hvas CL, Dahlerup JF, et al. Severe Fatigue in Inflammatory Bowel Disease: Dopaminergic Therapy With Modafinil or Vitamin Therapy With Thiamine. Clin Gastroenterol Hepatol. 2024. PMID: 38508480. doi:10.1016/j.cgh.2024.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。